Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors
- 1 July 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (13) , 3877-3880
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Targeting Oncogenic ALK: A Promising Strategy for Cancer TreatmentMolecular Cancer Therapeutics, 2011
- Inhibitors of anaplastic lymphoma kinase: a patent reviewExpert Opinion on Therapeutic Patents, 2010
- Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor ActivityACS Medicinal Chemistry Letters, 2010
- Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and NeuroblastomaAnti-Cancer Agents in Medicinal Chemistry, 2010
- GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancersMolecular Cancer Therapeutics, 2009
- Anaplastic lymphoma kinase: signalling in development and diseaseBiochemical Journal, 2009
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapyExpert Review of Anticancer Therapy, 2009
- The anaplastic lymphoma kinase in the pathogenesis of cancerNature Reviews Cancer, 2008
- Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivoMolecular Cancer Therapeutics, 2007
- Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALKProceedings of the National Academy of Sciences, 2007